Compositions, devices, and methods of mitigating lipoprotein interference in in vitro diagnostic assays for hydrophobic analytes
Methods of mitigating lipoprotein interference in in vitro diagnostic assays for target hydrophobic analytes are disclosed, as well as compositions, kits, and devices useful in said methods. A pretreatment reagent is utilized that includes at least one enzyme that digests lipoprotein.
1. A microfluidics device for use in a clinical chemistry instrument, the microfluidics device comprising:
at least one compartment capable of receiving a sample suspected of containing a target hydrophobic analyte, wherein the at least one compartment comprises:
a pretreatment reagent that digests lipoprotein particles, wherein the pretreatment reagent comprises protease, lipase, and a cofactor for lipase; and
at least one assay reagent capable of detecting a hydrophobic analyte for determining a concentration of target hydrophobic analyte present in the sample.
2. The microfluidics device of claim 1 , wherein the microfluidics device is further defined as comprising at least two compartments, wherein the pretreatment reagent is disposed in a first compartment that is capable of receiving the sample, and the at least one assay reagent is disposed in a second compartment that is capable of being in fluidic communication with the first compartment, and wherein the second compartment is a read chamber in which the detection assay for determining a concentration of target hydrophobic analyte present in the sample is performed.
3. The microfluidics device of claim 1 , wherein lipase is present in the pretreatment reagent at a concentration in a range of from about 0.1 mg/mL to about 20 mg/mL.
4. The microfluidics device of claim 1 , wherein the target hydrophobic analyte is selected from the group consisting of vitamin D, tacrolimus, sirolimus, everolimus, estrogen, estrone, estradiol, estriol, alfatradiol, cyclosporine, ethinylestradiol, esterified estrogens, moxestrol, quinestrol, progestins, progesterone, androgens, testosterone, dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), DHEA sulfate, androstenedione, aldosterone, cortisol, catecholamine, 25-hydroxy Vitamin D2, 25-hydroxy Vitamin D3, 1,25-dihydroxy Vitamin D2, and 1,25-dihydroxy Vitamin D3.
5. The microfluidics device of claim 1 , wherein the at least one assay reagent is further defined as an immunoassay reagent.
6. The microfluidics device of claim 1 , wherein the cofactor for lipase comprises bile acid and/or a salt thereof.
7. The microfluidics device of claim 1 , wherein the pretreatment reagent further comprises a surfactant.
8. The microfluidics device of claim 1 , wherein the pretreatment reagent further comprises pepsin.
9. The microfluidics device of claim 1 , wherein the pretreatment reagent further comprises amylase.
10. A microfluidics device for use in a clinical chemistry instrument, the microfluidics device comprising:
at least one compartment capable of receiving a sample suspected of containing a target hydrophobic analyte, wherein the at least one compartment comprises:
a pretreatment reagent that digests lipoprotein particles, wherein the pretreatment reagent comprises protease, lipase, and bile acid and/or a salt thereof; and
at least one assay reagent capable of detecting a hydrophobic analyte for determining a concentration of target hydrophobic analyte present in the sample.
11. The microfluidics device of claim 10 , wherein the pretreatment reagent further comprises at least one additional substance, wherein the at least one additional substance is selected from the group consisting of amylase, pepsin, a surfactant, and combinations thereof.
12. The microfluidics device of claim 10 , wherein lipase is present in the pretreatment reagent at a concentration in a range of from about 0.1 mg/mL to about 20 mg/mL.
13. The microfluidics device of claim 10 , wherein the target hydrophobic analyte is selected from the group consisting of vitamin D, tacrolimus, sirolimus, everolimus, estrogen, estrone, estradiol, estriol, alfatradiol, cyclosporine, ethinylestradiol, esterified estrogens, moxestrol, quinestrol, progestins, progesterone, androgens, testosterone, dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), DHEA sulfate, androstenedione, aldosterone, cortisol, catecholamine, 25-hydroxy Vitamin D2, 25-hydroxy Vitamin D3, 1,25-dihydroxy Vitamin D2, and 1,25-dihydroxy Vitamin D3.
14. The microfluidics device of claim 10 , wherein the at least one assay reagent is further defined as an immunoassay reagent.
15. A microfluidics device for use in a clinical chemistry instrument, the microfluidics device comprising:
at least one compartment capable of receiving a sample suspected of containing a target hydrophobic analyte, wherein the at least one compartment comprises:
a pretreatment reagent that digests lipoprotein particles, wherein the pretreatment reagent comprises protease, lipase, bile acid and/or a salt thereof, and at least one surfactant; and
at least one immunoassay reagent capable of detecting a hydrophobic analyte for determining a concentration of target hydrophobic analyte present in the sample.
16. The microfluidics device of claim 15 , wherein the target hydrophobic analyte is selected from the group consisting of vitamin D, tacrolimus, sirolimus, everolimus, estrogen, estrone, estradiol, estriol, alfatradiol, cyclosporine, ethinylestradiol, esterified estrogens, moxestrol, quinestrol, progestins, progesterone, androgens, testosterone, dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), DHEA sulfate, androstenedione, aldosterone, cortisol, catecholamine, 25-hydroxy Vitamin D2, 25-hydroxy Vitamin D3, 1,25-dihydroxy Vitamin D2, and 1,25-dihydroxy Vitamin D3.